FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

wasnington,	D.C.	20549	

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
netruction 1(h)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name an COLLI (Last) 1235 RA (Street) REDWO CITY	3. D 07/	Issuer Name and Ticker or Trading Symbol SOLENO THERAPEUTICS INC [SLNO] 3. Date of Earliest Transaction (Month/Day/Year) 07/06/2017 4. If Amendment, Date of Original Filed (Month/Day/Year)									Relationship of Reporting Person(s) to Issuer theck all applicable) X Director X 10% Owner Officer (give title below) Individual or Joint/Group Filing (Check Applicable ne) X Form filed by One Reporting Person Form filed by More than One Reporting				Owner (specify) Applicable son				
(City)	(St	ate) (.	Zip)												Pers				
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transact Date (Month/Day					ction	ion 2A. Deemed Execution Date,			quired, Disposed of, or Benefic 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) o Disposed Of (D) (Instr. 3, 4 a					r 5. Amount of			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
					Code				v	Amount	(A) (D)	or Pr	ce	Report Transa				(Instr. 4)	
Common	Stock			07/06/	2017				A		10,793(1) /	\$ \$0).61 ⁽²⁾	13	3,357	D		
Common	Stock														7,2	7,251,728 I See footnot			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	vative rity or Exercise Price of Derivative Security Conversion or Exercise Price of Derivative Security Price of Deriv		Transa Code (5. Nu of Deriv Secul Acqu (A) or Dispo of (D) (Instrand 5	ative rities ired osed	6. Date Exercisable and Expiration Date (Month/Day/Year) Date Exercisable Expiration Date			7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4) Amoun or Numbe of Title Shares		nt er		9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		

Explanation of Responses:

- 1. Effective January 1, 2017, annual board and committee retainers payable to directors will be made in equivalent shares of the Issuer's common stock, on a quarterly basis.
- 2. The number of shares issuable in lieu of cash retainers was determined using the closing price per share of Issuer common stock on July 6, 2017, or \$0.61.
- 3. Consists of shares of held by Forward Ventures V, L.P., or Forward Ventures. Mr. Collinson is a managing member of Forward Ventures and has shared voting power over the shares of Common Stock beneficially owned by Forward Ventures. Mr. Collinson disclaims beneficial ownership of such securities, except to the extent, if any, of his pecuniary interest therein.

Remarks:

/s/ David O'Toole, Attorney-in-

** Signature of Reporting Person

07/17/2017

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.